Mr Alexander Richards

2024

• Rodriguez, V. et al. 2024. Polygenic and polyenvironment interplay in schizophrenia-spectrum disorder and affective psychosis; the EUGEI first episode study. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders, article number: sbae207. (10.1093/schbul/sbae207)
• Austin-Zimmerman, I. et al. 2024. The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies. Psychological Medicine (10.1017/S0033291724002058)
• Trastulla, L. et al. 2024. Distinct genetic liability profiles define clinically relevant patient strata across common diseases. Nature Communications 15, article number: 5534. (10.1038/s41467-024-49338-2)
• D'Andrea, G. et al. 2024. Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study. Psychological Medicine 54(8), pp. 1810-1823. (10.1017/S0033291723003781)

2023

• Trotta, G. et al. 2023. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study. Psychological Medicine 53(15), article number: 7375. (10.1017/S0033291723000995)
• Rodriguez, V. et al. 2023. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. Psychological Medicine 53(8), pp. 3396-3405. (10.1017/S0033291721005456)
• Fusar-Poli, L. et al. 2023. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. Psychiatry Research 323, article number: 115184. (10.1016/j.psychres.2023.115184)
• Ferraro, L. et al. 2023. First-episode psychosis patients who deteriorated in the premorbid period do not have higher polygenic risk scores than others: A cluster analysis of EU-GEI data. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49(1), pp. 218-227. (10.1093/schbul/sbac100)

2022

• Tripoli, G. et al. 2022. Facial emotion recognition in psychosis and associations with polygenic risk for schizophrenia: findings from the multi-center EU-GEI case-control study. Schizophrenia Bulletin 48(5), pp. 1104-114. (10.1093/schbul/sbac022)
• Richards, A. et al. 2022. Genetic liabilities differentiating bipolar disorder, schizophrenia and major depression and phenotypic heterogeneity in bipolar disorder. JAMA Psychiatry 79(10), pp. 1032-1039. (10.1001/jamapsychiatry.2022.2594)
• Paquin, V. et al. 2022. Age- and sex-specific associations between risk scores for schizophrenia and self-reported health in the general population. Social Psychiatry and Psychiatric Epidemiology (10.1007/s00127-022-02346-3)
• van Os, J. et al. 2022. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine 52(10), pp. 1910-1922. (10.1017/S0033291720003748)
• Henquet, C. et al. 2022. A replication study of JTC bias, genetic liability for psychosis and delusional ideation. Psychological Medicine 52(9), pp. 1777-1783. (10.1017/S0033291720003578)
• Trubetskoy, V. et al. 2022. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. Nature 604, pp. 502-508. (10.1038/s41586-022-04434-5)
• Fusar-Poli, L. et al. 2022. Examining facial emotion recognition as an intermediate phenotype for psychosis: findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 113, article number: 110440. (10.1016/j.pnpbp.2021.110440)

2021

• Tosato, S. et al. 2021. Obstetric complications and polygenic risk score: which role in predicting a severe short-term outcome in psychosis?. Genes 12(12), article number: 1895. (10.3390/genes12121895)
• Ajnakina, O. et al. 2021. Duration of untreated psychosis in first-episode psychosis is not associated with common genetic variants for major psychiatric conditions: results from the multi-center EU-GEI study. Schizophrenia Bulletin 47(6), pp. 1653-1662. (10.1093/schbul/sbab055)
• Quattrone, D. et al. 2021. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Translational Psychiatry 11(1), article number: 423. (10.1038/s41398-021-01526-0)
• Legge, S. et al. 2021. Associations between schizophrenia polygenic liability, symptom dimensions, and cognitive ability in schizophrenia. JAMA Psychiatry 78(10), pp. 1143-1151. (10.1001/jamapsychiatry.2021.1961)
• Hubbard, L. et al. 2021. Rare copy number variations are associated with poorer cognition in schizophrenia. Biological Psychiatry 90(1), pp. 28-34. (10.1016/j.biopsych.2020.11.025)
• Tripoli, G. et al. 2021. Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. Psychological Medicine 51(4), pp. 623-633. (10.1017/S003329171900357X)
• Erzin, G. et al. 2021. Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Psychiatry 64(1), article number: e25. (10.1192/j.eurpsy.2021.19)
• Hannon, E. et al. 2021. DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. eLife 10, article number: e58430. (10.7554/eLife.58430)
• Hasmi, L. et al. 2021. What makes the psychosis 'clinical high risk' state risky: psychosis itself or the co-presence of a non-psychotic disorder?. Epidemiology and Psychiatric Sciences 30, article number: e53. (10.1017/S204579602100041X)

2020

• Pries, L. et al. 2020. Association of recent stressful life events with mental and physical health in the context of genomic and exposomic liability for schizophrenia. JAMA Psychiatry 77(12), pp. 1296-1304. (10.1001/jamapsychiatry.2020.2304)
• Pries, L. et al. 2020. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiology and Psychiatric Sciences 29, article number: e182. (10.1017/S2045796020000943)
• van Os, J. et al. 2020. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study. Psychological Medicine 50(11), pp. 1884-1897. (10.1017/S003329171900196X)
• Akingbuwa, W. A. et al. 2020. Genetic associations between childhood psychopathology and adult depression and associated traits in 42 998 individuals. JAMA Psychiatry 77(7), pp. 715-728. (10.1001/jamapsychiatry.2020.0527)
• Riglin, L. et al. 2020. Using genetics to examine a general liability to childhood psychopathology. Behavior Genetics 50, pp. 213-220. (10.1007/s10519-019-09985-4)
• Ferraro, L. et al. 2020. Premorbid adjustment and IQ in patients with first-episode psychosis: a multisite case-control study of their relationship with cannabis use. Schizophrenia Bulletin 46(3), pp. 517-529. (10.1093/schbul/sbz077)
• Lewis, K. J. et al. 2020. Comparison of genetic liability for sleep traits among individuals with Bipolar Disorder I or II and control participants. JAMA Psychiatry 77(3), pp. 303-310. (10.1001/jamapsychiatry.2019.4079)
• Richards, A. et al. 2020. The relationship between polygenic risk scores and cognition in schizophrenia. Schizophrenia Bulletin 46(2), pp. -. (10.1093/schbul/sbz061)
• Rees, E. et al. 2020. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. Nature Neuroscience 23(2), pp. 179-184. (10.1038/s41593-019-0565-2)

2019

• Pries, L. et al. 2019. Estimating exposome score for schizophrenia using predictive modeling approach in two independent samples: the results from the EUGEI study. Schizophrenia Bulletin 45(5), pp. 960-965. (10.1093/schbul/sbz054)
• Guloksuz, S. et al. 2019. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry 18(2), pp. 173-182. (10.1002/wps.20629)
• Quattrone, D. et al. 2019. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU GEI study. Psychological Medicine 49(8), pp. 1378-1391. (10.1017/S0033291718002131)
• Stahl, E. A. et al. 2019. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics 51, pp. 793-803. (10.1038/s41588-019-0397-8)
• Rees, E. et al. 2019. Targeted sequencing of 10,198 samples confirms abnormalities in neuronal activity and implicates voltage-gated sodium channels in schizophrenia pathogenesis. Biological Psychiatry 85(7), pp. 554-562. (10.1016/j.biopsych.2018.08.022)
• Harold, D. et al. 2019. Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 180(3), pp. 223-231. (10.1002/ajmg.b.32716)
• Richards, A. et al. 2019. Associations between schizophrenia genetic risk, anxiety disorders and manic/hypomanic episode in a New Zealand longitudinal population cohort study. British Journal of Psychiatry 214(2), pp. 96-102. (10.1192/bjp.2018.227)

2018

• Riglin, L. et al. 2018. The impact of schizophrenia and mood disorder risk alleles on emotional problems: investigating change from childhood to middle age. Psychological Medicine 48(13), pp. 2153-2158. (10.1017/S0033291717003634)
• Donohoe, G. et al. 2018. Genetically predicted complement component 4A expression: effects on memory function and middle temporal lobe activation. Psychological Medicine 48(10), pp. 1608-1615. (10.1017/S0033291717002987)
• Ruderfer, D. M. et al. 2018. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173(7), pp. 1705-1715.e16. (10.1016/j.cell.2018.05.046)
• Cosgrove, D. et al. 2018. Effects of MiR-137 genetic risk score on brain volume and cortical measures in patients with schizophrenia and controls. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 177(3), pp. 369-376. (10.1002/ajmg.b.32620)

2017

• Cosgrove, D. et al. 2017. Cognitive characterization of schizophrenia risk variants involved in synaptic transmission: evidence of CACNA1C's role in working memory. Neuropsychopharmacology 42, pp. 2612-2622. (10.1038/npp.2017.123)
• Green, E. K. et al. 2017. Genome-wide significant locus for Research Diagnostic Criteria Schizoaffective Disorder Bipolar type. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 174(8), pp. 767-771. (10.1002/ajmg.b.32572)
• Leonenko, G. et al. 2017. Mutation intolerant genes and targets of FMRP are enriched for nonsynonymous alleles in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 174(7), pp. 724-731. (10.1002/ajmg.b.32560)
• Legge, S. E. et al. 2017. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry 22, pp. 1502-1508. (10.1038/mp.2016.97)
• Mihaljevic, M. et al. 2017. The emerging role of the FKBP5 gene polymorphisms in vulnerability-stress model of schizophrenia: further evidence from a Serbian population. European Archives of Psychiatry and Clinical Neuroscience 267(6), pp. 527-539. (10.1007/s00406-016-0720-7)
• Riglin, L., Collishaw, S., Richards, A., Thapar, A., Maughan, B., O'Donovan, M. C. and Thapar, A. 2017. Schizophrenia polygenic risk score and psychotic risk detection - authors' reply. The Lancet Psychiatry 4(3), pp. 188-189. (10.1016/S2215-0366(17)30052-4)
• Marshall, C. R. et al. 2017. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics 49, pp. 27-35. (10.1038/ng.3725)
• Cosgrove, D. et al. 2017. MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls. Translational Psychiatry 7(1), pp. e1012. (10.1038/tp.2016.286)
• Riglin, L., Collishaw, S., Richards, A., Thapar, A. K., Maughan, B., O'Donovan, M. C. and Thapar, A. 2017. Schizophrenia risk alleles and neurodevelopmental outcomes in childhood: a population-based cohort study. Lancet Psychiatry 4(1), pp. 57-62. (10.1016/S2215-0366(16)30406-0)

2016

• Whitton, L. et al. 2016. Cognitive analysis of schizophrenia risk genes that function as epigenetic regulators of gene expression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 171(8), pp. 1170-1179. (10.1002/ajmg.b.32503)
• Franke, B. et al. 2016. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nature Neuroscience 19(3), pp. 420-431. (10.1038/nn.4228)
• Richards, A. et al. 2016. Exome arrays capture polygenic rare variant contributions to schizophrenia. Human Molecular Genetics 25(5), pp. 1001-1007. (10.1093/hmg/ddv620)

2015

• Loohuis, L. M. O. et al. 2015. Genome-wide burden of deleterious coding variants increased in schizophrenia. Nature Communications 6, article number: 7501. (10.1038/ncomms8501)
• Jones, L. et al. 2015. Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia 11(6), pp. 658-671. (10.1016/j.jalz.2014.05.1757)
• Rees, E. et al. 2015. Analysis of exome sequence in 604 trios for recessive genotypes in schizophrenia. Translational Psychiatry 5(7), article number: e607. (10.1038/tp.2015.99)

2014

• Gusev, A. et al. 2014. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. American Journal of Human Genetics 95(5), pp. 535-552. (10.1016/j.ajhg.2014.10.004)
• Ripke, S. et al. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510), pp. 421-427. (10.1038/nature13595)
• Craddock, N. J. et al. 2014. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophrenia Bulletin 40(4), pp. 729-736. (10.1093/schbul/sbu069)
• Escott-Price, V. et al. 2014. Gene-wide analysis detects two new susceptibility genes for Alzheimer's Disease. PLoS ONE 9(6), article number: e94661. (10.1371/journal.pone.0094661)
• Rees, E. et al. 2014. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Human Molecular Genetics 23(6), pp. 1669-1676. (10.1093/hmg/ddt540)
• Rees, E. et al. 2014. Analysis of copy number variations at 15 schizophrenia-associated loci. British Journal of Psychiatry 204(2), pp. 108-114. (10.1192/bjp.bp.113.131052)

2013

• Rees, E. et al. 2013. Evidence that duplications of 22q11.2 protect against schizophrenia. Molecular Psychiatry n/a (10.1038/mp.2013.156)
• Zammit, S. et al. 2013. A population-based study of genetic variation and psychotic experiences in adolescents. Schizophrenia Bulletin 40(6), pp. 1254-1262. (10.1093/schbul/sbt146)
• Ripke, S. et al. 2013. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics 45(10), pp. 1150-1159. (10.1038/ng.2742)
• Hamshere, M. L. et al. 2013. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Molecular Psychiatry 18(6), pp. 708-712. (10.1038/mp.2012.67)
• Kirov, G. et al. 2013. The penetrance of copy number variations for schizophrenia and developmental delay. Biological Psychiatry 75(5), pp. 378-385. (10.1016/j.biopsych.2013.07.022)

2012

• Richards, A. et al. 2012. Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain. Molecular Psychiatry 17(2), pp. 193-201. (10.1038/mp.2011.11)
• Gerrish, A. et al. 2012. The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's Disease. Journal of Alzheimer's Disease 28(2), pp. 377-387. (10.3233/JAD-2011-110824)

2011

• Hollingworth, P. et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics 43(5), pp. 429-435. (10.1038/ng.803)
• Smith, R. L. et al. 2011. Analysis of neurogranin (NRGN) in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156B(5), pp. 532-535. (10.1002/ajmg.b.31191)

2010

• Richards, A. 2010. Gene expression data and neuropsychiatric disease. PhD Thesis, Cardiff University.

2008

• Richards, A. L., Holmans, P. A., O'Donovan, M. C., Owen, M. J. and Jones, L. 2008. A comparison of four clustering methods for brain expression microarray data. BMC Bioinformatics 9, article number: 490. (10.1186/1471-2105-9-490)
• Bray, N. J. et al. 2008. Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1. Human Molecular Genetics 17(8), pp. 1169-1174. (10.1093/hmg/ddn006)